Cancer treatment and research communications最新文献

{"title":"The prognostic role of circulating CA19–9 and CEA in patients with colorectal cancer","authors":"Mathias H. Gramkow ,&nbsp;Camilla S. Mosgaard ,&nbsp;Jakob V. Schou ,&nbsp;Ellen Hein Nordvig ,&nbsp;Troels Gammeltoft Dolin ,&nbsp;Jakob Lykke ,&nbsp;Dorte L. Nielsen ,&nbsp;Per Pfeiffer ,&nbsp;Camilla Qvortrup ,&nbsp;Mette K. Yilmaz ,&nbsp;Ole Larsen ,&nbsp;Stig E. Bojesen ,&nbsp;Benny V. Jensen ,&nbsp;Julia S. Johansen","doi":"10.1016/j.ctarc.2025.100907","DOIUrl":"10.1016/j.ctarc.2025.100907","url":null,"abstract":"<div><h3>Background</h3><div>Carcinoembryonic antigen (CEA) is the only prognostic circulating biomarker used in clinical practice for recurrence free (RFS), progression free (PFS) and overall survival (OS) in patients with colorectal cancer (CRC). Not all CRC tumors express this protein and carbohydrate antigen (CA)19–9 has been proposed as an adjunctive in prognostication. We aimed to test if CA19–9 yielded additional information to CEA regarding prognosis.</div></div><div><h3>Patients and methods</h3><div>We included 886 patients with CRC across eight clinical cohorts. Preoperative serum samples were collected from 376 patients with stage I-III CRC and from 510 with metastatic (m)CRC before 1st (<em>n</em> = 233)^, 3rd (<em>n</em> = 178) and 3rd/4th (<em>n</em> = 99) line chemotherapy. CA19–9 and CEA were determined by routine assays, the values were log-2 transformed and entered as variables in Cox regression models with RFS (stage I-III), PFS and OS as the outcomes, adjusted for age, sex, and site of primary tumor and mutual adjustment between CA199 and CEA. Random effects meta-analyses were conducted for stage I-III,1st line, and 3rd/4th line mCRC cohorts separately.</div></div><div><h3>Results</h3><div>Meta-analyses showed that higher pre-treatment CA19–9 and CEA were associated with shorter RFS (CA19–9: hazard ratio per doubling of concentration (HR)=1.20, 95 % confidence interval (CI) 1.05–1.38; CEA: HR=1.22, 95 % CI 1.05–1.41) in stage I-III CRC. Only higher CEA was associated with shorter OS in 1st line mCRC (HR=1.07, 95 % CI 1.00-1.07).</div></div><div><h3>Conclusion</h3><div>CA19–9 might aid in identifying patients with a high risk of recurrence after primary radical resection. Further studies are needed to validate these findings.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100907"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143680700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Complete response of unilateral primary lacrimal sac diffuse large B-cell lymphoma treated without radiotherapy in an adult: A rare case report and review of the literature","authors":"Suzana Sultan ,&nbsp;Tasnim Ibrahim ,&nbsp;Ali Habib ,&nbsp;Firas Hussein","doi":"10.1016/j.ctarc.2025.100897","DOIUrl":"10.1016/j.ctarc.2025.100897","url":null,"abstract":"<div><div>Diffuse large B-cell lymphoma (DLBCL) manifests extranodally in one-third of non-Hodgkin lymphoma (NHL) cases. However, primary DLBCL of the lacrimal sac is very rare. A 54-year-old man presented with a 5-month history of right-sided epiphora. He visited three private clinics and was misdiagnosed with conjunctivitis. Later, a painless mass in the right lacrimal area prompted an MRI scan followed by a CT scan, which suggested a lacrimal sac mass. The mass was surgically excised, and histopathology and immunohistochemistry revealed DLBCL. A PET/CT scan was done instead of bone marrow biopsy, which excluded systemic lymphomatous involvement, confirming the diagnosis of primary right lacrimal sac DLBCL. The patient received six standard cycles of the R-CHOP regimen. Although no radiotherapy was used, CT findings after the completion of the 4th cycle showed a complete response (CR), which was maintained in a follow-up CT scan 2 months after chemotherapy completion. Despite the rarity of the tumor, it should be considered in the differential diagnosis of long-standing or unresponsive inflammatory conditions. Radiotherapy-free management could achieve CR in limited-stage DLBCL.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100897"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143642646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ezetimibe mediated RPS6KA2 inhibits colorectal cancer proliferation via PCSK9/MAPK signaling pathway","authors":"Yu Wang ,&nbsp;Yuting Wang ,&nbsp;Huabin Gao ,&nbsp;Lin Chen,&nbsp;Shuai Zheng,&nbsp;Yongyu Chen,&nbsp;Huijuan Shi,&nbsp;Anjia Han","doi":"10.1016/j.ctarc.2025.100899","DOIUrl":"10.1016/j.ctarc.2025.100899","url":null,"abstract":"<div><div>To investigate the effect and molecular mechanism of ezetimibe on colorectal cancer (CRC), our study found that ezetimibe significantly inhibited the proliferation and progression of CRC. Further study showed that RPS6KA2 might be the target gene of ezetimibe treatment on CRC. RPS6KA2 expression was significantly lower in human CRC tissue samples and associated with T classification and vascular invasion of tumor cells. RPS6KA2 inhibited proliferation, migration, and invasion of CRC cells. The underlying mechanisms indicated that interaction between RPS6KA2 and PCSK9 was observed within the cytoplasmic compartment of CRC cells. RPS6KA2 suppressed PCSK9 and MAPK signaling pathway in CRC cells. BI-D1780 which is an inhibitor of RPS6KA2 increased PCSK9 and MAPK signaling pathway related proteins expression in SW620 cells. However, an inhibitor or stimulator of MAPK did not affect RPS6KA2 and PCSK9 expression, respectively. In vivo, CRC cells with RPS6KA2 or PCSK9 overexpression could inhibit or promote tumor growth and metastasis, respectively. PCSK9 promoted proliferation, migration, and invasion of CRC cells. PCSK9 expression was higher in human CRC samples and associated with N classification and TNM stage of CRC. In conclusion, our study firstly suggests that ezetimibe suppresses CRC progression by upregulating RPS6KA2 while downregulating PCSK9/MAPK signaling pathway.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"43 ","pages":"Article 100899"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143668762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A systemic review on chemotherapy induced nausea and vomiting- risk and clinical management with alternative therapies","authors":"Derangula Lavanya ,&nbsp;VelugotlaPranathi Prasanna ,&nbsp;Asma Firdous ,&nbsp;Sneha Thakur","doi":"10.1016/j.ctarc.2025.100938","DOIUrl":"10.1016/j.ctarc.2025.100938","url":null,"abstract":"<div><div>Chemotherapy-induced nausea and vomiting (CINV) affects up to 80 % of cancer patients, significantly impacts the health in terms of their quality of life and straining healthcare resources. CINV is categorized into anticipatory, acute, and delayed types. Risk factors include younger age, female sex, a history of CINV, and the emetogenic potential of the chemotherapy agents. Drugs like cisplatin and anthracycline-cyclophosphamide combinations are highly emetogenic and pose the greatest risk. Advances in managing CINV include evidence-based guidelines and the use of antiemetic medications such as 5-HT3 receptor antagonists, NK-1 receptor antagonists, and corticosteroids. These measures have reduced vomiting incidents, but complete control of nausea remains challenging. Up to 60 % of patients still experience delayed nausea, and anticipatory nausea and vomiting affect up to 30 % and 20 % of patients, respectively, by the fourth treatment cycle. Clinical and alternative therapies are though effective, research suggests integrated management for CINV. Tailored approach is needed as it has both psychological and physiological influence. To overcome the challenges, the guidelines and antiemetic regimens should be improved according to individual patient evaluation and awareness is necessary. Research is ongoing to develop targeted therapies that combine pharmacological and behavioral interventions to improve CINV management, especially for patients who do not respond well to current antiemetic treatments.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100938"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144178815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The utility of immunohistochemistry-based biomarkers in predicting the pathological complete response in early-stage triple-negative breast cancer","authors":"Chikako Funasaka ,&nbsp;Takahiro Kogawa ,&nbsp;Naoya Sakamoto ,&nbsp;Shota Kusuhara ,&nbsp;Takehiro Nakao ,&nbsp;Hiromichi Nakajima ,&nbsp;Chihiro Kondoh ,&nbsp;Kenichi Harano ,&nbsp;Nobuaki Matsubara ,&nbsp;Ako Hosono ,&nbsp;Yoichi Naito ,&nbsp;Mototsugu Shimokawa ,&nbsp;Rurina Watanuki ,&nbsp;Yuji Yamashita ,&nbsp;Chisako Yamauchi ,&nbsp;Tatsuya Onishi ,&nbsp;Genichiro Ishii ,&nbsp;Toru Mukohara","doi":"10.1016/j.ctarc.2025.100941","DOIUrl":"10.1016/j.ctarc.2025.100941","url":null,"abstract":"<div><div>Triple-negative breast cancer (TNBC) is a highly aggressive subtype of BC. A pathological complete response (pCR) to neoadjuvant chemotherapy is strongly associated with a favorable TNBC prognosis; however, established predictors of pCR, including tumor-infiltrating lymphocytes (TILs), are often not adequately reliable in the clinic. This study evaluated the utility of immunohistochemistry (IHC)-based markers and TILs in predicting pCR in early-stage TNBC. This study enrolled 61 women with stage I–III TNBC who were treated at our institution between January 2013 and December 2019. Pathological data were collected from electronic medical records, while IHC data were obtained from preoperative biopsy specimens. Fisher’s test, multivariable logistic regression, and correlation analyses were used to identify biomarker candidates and their interactions. The majority of the patients had stage II or III invasive ductal TNBC. The pCR rate was 31 % (19/61). High TIL frequencies (≥ 40 %) and high Ki-67 (≥ 40 %) levels were associated with pCR. Among the patients with high TIL frequencies, AR-negative patients had a higher pCR rate than AR-positive patients (55.0 % versus 16.7 %; <em>p</em> = 0.71). Vimentin negativity correlated with high TIL frequencies (<em>p</em> = 0.02). High TIL frequencies and high Ki-67 levels were independently associated with an increased likelihood of achieving a pCR. The combination of high TIL frequencies and high Ki-67 levels was predictive of pCR in patients with primary TNBC, while AR and vimentin represent candidate markers that require further validation. Further studies should evaluate the performance of these markers in combination with other biomarkers and in the context of immune-checkpoint blockade.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100941"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting lipid metabolism to overcome tamoxifen resistance in breast cancer: Evaluating the synergistic therapeutic potential of quercetin","authors":"Radwa M. Rifaat,&nbsp;Marwa W. Kamel,&nbsp;Marwa Sharaky,&nbsp;Yasmin M. Attia,&nbsp;Samia A. Shouman","doi":"10.1016/j.ctarc.2025.100953","DOIUrl":"10.1016/j.ctarc.2025.100953","url":null,"abstract":"<div><div>Breast cancer remains the most prevalent malignancy among women globally, with hormone receptor-positive subtypes representing the majority of cases. Despite significant advances in treatment, resistance to Tamoxifen, a cornerstone therapy for estrogen receptor-positive (ER⁺) breast cancer, poses a critical challenge, affecting up to 50 % of patients. Emerging evidence suggests that dysregulated lipid metabolism plays a pivotal role in breast cancer progression and therapy resistance. This systematic review aims to explore the intricate relationship between lipid metabolism and Tamoxifen resistance, with a particular focus on the potential therapeutic synergy of combining Tamoxifen with lipid metabolism modulators, such as Quercetin. We systematically searched PubMed, Scopus, Web of Science, and the Cochrane Library for studies published between 2000 and 2023, examining the role of lipid metabolic pathways in breast cancer and the impact of Quercetin on enhancing Tamoxifen efficacy. The findings suggest that targeting key enzymes involved in lipid metabolism, including fatty acid synthase (FASN) and acetyl-CoA carboxylase (ACC), may impair cancer cell survival mechanisms and sensitize tumors to Tamoxifen. The combination of Tamoxifen and Quercetin appears to exhibit synergistic effects, enhancing apoptosis and reducing cell proliferation more effectively than either agent alone. This review highlights the potential of combining Tamoxifen with Quercetin as a therapeutic strategy to overcome Tamoxifen resistance, providing a rationale for further clinical trials to investigate this combination therapy.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100953"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144307663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing the oncologic outcomes of breast-conserving surgery for breast cancer patients performed either upfront or following neoadjuvant chemotherapy: a matched retrospective cohort","authors":"Hazem Assi ,&nbsp;Malak Ghezzawi ,&nbsp;Hussein Nassar ,&nbsp;Cynthia Alame ,&nbsp;Jason El Azzi ,&nbsp;Bashar Hassan ,&nbsp;Selim Gebran ,&nbsp;Melhem Nehme ,&nbsp;Zeina Hassan ,&nbsp;Ziad Salem ,&nbsp;Jaber Al-Abbas ,&nbsp;Eman Sbaity","doi":"10.1016/j.ctarc.2025.100984","DOIUrl":"10.1016/j.ctarc.2025.100984","url":null,"abstract":"<div><h3>Background</h3><div>Neoadjuvant chemotherapy (NACT) is used to reduce breast cancer size before surgery, allowing for breast conservation surgery (BCS) instead of mastectomy. However, concerns exist about higher positive margins and local recurrence rates.</div></div><div><h3>Aims</h3><div>This study compared the incidence of positive margins, local recurrence rates, and other oncologic outcomes of BCS performed either upfront or after NACT.</div></div><div><h3>Methods</h3><div>We conducted a retrospective matched cohort study of 122 patients treated at the American University of Beirut Medical Center between July 2011 and September 2016. Patients who underwent BCS whether upfront or after chemotherapy were matched 1:1 based on disease stage and molecular subtype.</div></div><div><h3>Results</h3><div>We matched 61 breast cancer patients treated with BCS following NACT to those treated with upfront BCS. Patients in the NACT group were younger, with a mean age of 45 years compared to 52 years in the upfront group. In the NACT group, 31 (51.7 %) have high-grade disease. Most patients received adjuvant radiation therapy. Positive margins were found in 14 patients in the NACT group and 5 in the upfront group (<em>p</em> = 0.03). Local recurrence was 8.6 % in the NACT group versus 1.7 % in the upfront group (<em>p</em> = 0.086). 5 years disease free survival was significantly lower 81 % in the NACT group versus 95 % in the upfront group (<em>p</em> = 0.03). Overall survival was not significantly different in the NACT group compared to the upfront group (<em>p</em> = 0.574).</div></div><div><h3>Conclusion</h3><div>Breast cancer treated with BCS after NACT has a low incidence of positive margins and similar oncologic outcomes compared to BCS performed upfront.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"45 ","pages":"Article 100984"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145007677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics, incidence, and survival of unknown stage cancer: A US population-based study","authors":"Ray M. Merrill,&nbsp;Alida J. Johnson","doi":"10.1016/j.ctarc.2025.100949","DOIUrl":"10.1016/j.ctarc.2025.100949","url":null,"abstract":"<div><h3>Introduction</h3><div>This study examines the extent of unknown stage cancer incidence for 24 cancer sites in the U.S. based on reporting source, selected variables, and cancer lethality.</div></div><div><h3>Methods</h3><div>Analyses included 5,447,023 malignant cancer cases diagnosed during 2015–2021, collected by 22 population-based cancer registries in the Surveillance, Epidemiology, and End Results (SEER) Program. Poisson regression estimated adjusted rate ratios.</div></div><div><h3>Results</h3><div>Approximately 9.4 % of males and 7.2 % of females had unstaged cancer, significantly varying by reporting source. Levels of unstaged cancer identified by hospital, physician, or other; autopsy; death certificate; or nursing/convalescent home/hospice were 7.8 %, 32.6 %, 97.0 %, and 82.0 % in males and 5.8 %, 31.2 %, 97.1 %, and 82.4 % in females, respectively. Rates increased with age when the reporting source was hospital, physician, or other but decreased with age for autopsy, death certificate, or nursing/convalescence home/hospice. Unstaged cancer rates were similar between men and women (<em>r</em> = 0.93, <em>p</em> &lt; 0.0001, not including breast cancer). However, men were seen to have a 60 % higher rate of unstaged cancer (95 % CI 59 %-61 %) compared to women. Rates increased with age, decreased with income, and were 11 % (95 % CI 10 %-12 %) higher in Blacks (vs. Whites), and 11 % (95 % CI 10 %-12 %) higher in Hispanics (vs. non-Hispanics). A significant negative association was found between unstaged cancer percentages and 5-year relative survival rates for both sexes.</div></div><div><h3>Conclusions</h3><div>Males, older age, Blacks, Hispanics, and lower income patients are more susceptible to not receiving a cancer stage because of higher comorbid illness, more aggressive cancer, and less ability to pay for treatment.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100949"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144196427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of first-line pemetrexed plus carboplatin followed by pemetrexed maintenance in newly diagnosed and metastatic elderly non-squamous Non-Small Cell Lung Cancer (NSCLC): Real World Data (RWD) of a Galician and Mediterranean lung cancer group","authors":"Arias Ron David ,&nbsp;Álvarez Fernández Javier ,&nbsp;García Benito Carme ,&nbsp;Huidobro Vence Gerardo ,&nbsp;García Lorenzo Carme ,&nbsp;Santomé Couto Lucía ,&nbsp;Amenedo Gancedo Margarita ,&nbsp;Esquerdo Galiana Gaspar ,&nbsp;Areses Manrique María Carmen ,&nbsp;Fernández Núñez Natalia ,&nbsp;Lázaro Quintela Martín ,&nbsp;Casal Rubio Joaquín ,&nbsp;Afonso Afonso Francisco Javier ,&nbsp;Campos Balea Begoña ,&nbsp;García Mata Jesús ,&nbsp;Aversa Caterina ,&nbsp;Vázquez Estévez Sergio ,&nbsp;Fírvida Pérez Jose Luis","doi":"10.1016/j.ctarc.2025.100960","DOIUrl":"10.1016/j.ctarc.2025.100960","url":null,"abstract":"<div><h3>Background</h3><div>The role of Pemetrexed combined with platinum chemotherapy in newly diagnosed and metastatic non-squamous NSCLC is clearly defined since the results of Paramount trial. Currently, platinum chemotherapy plus immunotherapy has become the gold standard treatment in most of patients. Elderly patients are usually underrepresented in clinical trials and there is a lack of data in this setting. We analysed the efficacy and safety of platinum-pemetrexed chemotherapy in a cohort of newly diagnosed and metastatic elderly non-squamous NSCLC patients.</div></div><div><h3>Patients and methods</h3><div>In this multicentre, retrospective, real-world cohort, we collected all newly diagnosed and metastatic non-squamous NSCLC aged ≥70 years and treated with carboplatin-pemetrexed chemotherapy followed by pemetrexed maintenance. Patients characteristics, comorbidities and mutational status were described. Our objective is to analyse the efficacy and safety of doublet regimen in an elderly cohort.</div></div><div><h3>Results</h3><div>67 patients were included in the analysis. Median age was 75 years (70–84), mostly of them showed Performance status (PS) 1 (79 %) and 36 % presented with extrapulmonary metastases. 52 % of patients presented at least three comorbidities. Median PFS was 5.3 months (CI 95 % 4–6.6, <em>p</em> = 0.66) while median OS was 9.7 months (CI 95 % 8.3–11.1, <em>p</em> = 0.72). Fatigue (14 %) and neutropenia (12 %) were the most common grade 3–4 Adverse Event (AE), while asthenia (64 %) was the most common grade 1–2 AE.</div></div><div><h3>Conclusion</h3><div>Pemetrexed-based chemotherapy followed by pemetrexed maintenance is efficacious and safe in newly diagnosed and metastatic non-squamous NSCLC patients aged ≥70 years, achieving similar results in terms of survival and toxicity than pivotal trials. So, this doublet regimen may be considered as an alternative in patients who are not candidate for triplet regimen with platinum chemotherapy plus Immune Checkpoint Inhibitors (ICIs) or they don´t have access for them.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100960"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144842204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological description of genetic alterations and prognosis in Mexican patients with melanoma: a retrospective cohort","authors":"Katia F. Ávila-Fernández ,&nbsp;Héctor Martínez-Said ,&nbsp;Ivan R. González-Espinoza ,&nbsp;Rodrigo R. Flores-Mariñelarena ,&nbsp;Gabriela Juárez-Salazar ,&nbsp;Mariana Chiquillo-Dominguéz ,&nbsp;Abraham Castro-Ponce ,&nbsp;Julio C. Garibay-Díaz ,&nbsp;Jerónimo R. Rodríguez-Cid","doi":"10.1016/j.ctarc.2025.100973","DOIUrl":"10.1016/j.ctarc.2025.100973","url":null,"abstract":"<div><h3>Background</h3><div>Melanoma is currently the most aggressive skin cancer. It is currently categorized based on mutations that have been studied for their prognostic relevance.</div></div><div><h3>Objective</h3><div>Define the epidemiology of mutations in patients with melanoma in Mexico using the Next-Generation Sequencing technology and explore its prognosis utility in terms of prognosis.</div></div><div><h3>Methods</h3><div>A descriptive, multicentric, analytical, and retrospective study was conducted on sixteen patients with melanoma and NGS.</div></div><div><h3>Results</h3><div>Sixteen patients with nodular, lentiginous acral melanoma, and superficial extension were included. We found sixteen different mutations in the melanoma samples. The most frequent mutation in our population was the BRAF mutation (56.3 %); the CCND1 and NRAS mutations were found in 18.8 %. There was a statistically significant association between NRAS and mortality. Median progression-free survival was 27 months (95 % CI = 6.5–47.42 months) and median overall survival was 40.18 months (95 % CI = 19.03 – 61.3 months). The frequency of the mutations we found is similar to the ones reported in the literature, except for CD274, ROS1, and CDKN2A/B, which are more common in our population. We only found a prognostic value with NRAS, even though there is some evidence of mortality associated with other mutations.</div></div><div><h3>Conclusion</h3><div>NGS is a useful tool that can detect multiple mutations in the same patient. Detecting profiles with prognostic values and mutations for targeted therapy is an option for these patients, however, the usefulness of these results must be further studied in larger cohorts.</div></div>","PeriodicalId":9507,"journal":{"name":"Cancer treatment and research communications","volume":"44 ","pages":"Article 100973"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144773143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}